| Assessment Status | Rapid Review Complete |
| HTA ID | 23018 |
| Drug | Fostemsavir |
| Brand | Rukobia ® |
| Indication | Fostemsavir (Rukobia ®) in combination with other antiretrovirals, is indicated for the treatment of adults with multidrug resistant HIV-1 infection for whom it is otherwise not possible to construct a suppressive anti-viral regimen. |
| Assessment Process | |
| Rapid review commissioned | 27/03/2023 |
| Rapid review completed | 20/04/2023 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of fostemsavir compared with the current standard of care, on the basis of the proposed price. * |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
